CD177 Biomarker Measurement for Infection Risk Assessment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current clinical diagnostic tests lack the ability to identify patients at high risk for healthcare-associated infections, which are prevalent in medical facilities and contribute to increased morbidity, mortality, and healthcare costs, with existing methods failing to provide timely and effective risk assessment.

Innovation Solution

A method involving the measurement of CD177 gene expression in biological samples from patients, combined with other biomarkers, to determine the risk of healthcare-associated infections, allowing for early identification and targeted treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current clinical diagnostic tests are used, then general patient monitoring is available, but the ability to identify patients at high risk for healthcare-associated infections is lacking

Engineering Contradiction:
Improverisk assessment precisionVSAvoiddiagnostic test complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent extracts a specific biomarker (CD177) from the complex array of potential infection indicators to create a focused diagnostic test. By measuring only CD177 expression levels in neutrophils, the test achieves high precision in identifying patients at risk for healthcare-associated infections without requiring complex multi-parameter monitoring systems

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the measurement parameter from general clinical indicators to a specific molecular marker (CD177 gene expression). This parameter change enables precise identification of high-risk patients by detecting altered neutrophil function states that precede clinical infection manifestations

Inventive Principle:
Principle #35Parameter changes

2Reliability

If early identification methods are implemented, then patient mortality and healthcare costs can be reduced, but no clinical in vitro diagnostic test currently exists for this purpose

Engineering Contradiction:
Improveinfection risk prediction reliabilityVSAvoiddiagnostic test availability
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent replaces complex mechanical monitoring systems with a molecular-based diagnostic approach. By using RT-PCR or qPCR technology to measure CD177 mRNA expression, the test achieves reliable early identification of infection risk through biochemical detection rather than cumbersome clinical monitoring protocols

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

3Productivity

If comprehensive infection monitoring is performed, then infection detection capability is improved, but identification time remains delayed without specific biomarkers

Engineering Contradiction:
Improveinfection identification speedVSAvoididentification time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The patent performs preliminary detection of CD177 expression changes before clinical infection symptoms manifest. By measuring neutrophil functional alterations at the molecular level early in the infection process, the test enables proactive identification and intervention, reducing the time lag between infection onset and detection

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentUS20230250479A1Method for determining the risk of incidence of a care-related infection in a patient
Publication Date: 2023.08.10 BIOMERIEUX SA

AI summary

An in vitro or ex vivo method for determining the risk of incidence of a care-related infection includes a step of measuring the expression of CD177 in a biological sample from said patient.